clinicians to better understand and choose better treatment options for these populations. Keywords: Nicotinic antagonist, treatment resistance, major depressive disorder.
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The antidepressant-like effect induced by caloric restriction: possible involvement of orexin-A. 
Abstract

Palavras-chave:
Caloric restriction, antidepressant-like effect, BDNF Introduction: Evidence suggests that rats and mice submitted to caloric restriction perform better on learning and memory tests and show behavioral adaptation in animal models of depression. These effects may involve changes in neurotransmitters and neuropeptides important for modulating stress responses, like orexin A (OXA) and brain-derived neurotrophic factor (BDNF). OXA, a neuropeptide produced by neurons in the lateral hypothalamic and perifornical areas. OXA modulates the release of BDNF, a highly expressed neurotrophin, which mediates antidepressant-like effects through interaction with TrkB receptors. Our work tested the hypothesis that CR-induced behavioral effects would involve OXA and BDNF signaling. Methods: BALB/c mice were submiited to CR for 10 days (receiving 60% of the total energy supply based on the control animals) and exposed to forced swimming test (FST). Independent groups were pretreated with K252 (TrkB receptor antagonist; 80ug/kg, ip), SB-334867 (orexin-1 receptor antagonist, 10mg/kg,ip) or vehicle on days 1, 5 and 9 of CR, and were submitted to FST on the 10 th day. Results: CR induced an antidepressant-like effect when compared with ad libitum condition (Two-way ANOVA interaction: F 1,19 =5.287; t test, p<0,005) and this effect was reversed by the pre-treatment with SB-334867 (test t, p>0,005). CR effect was reproduced in the group treated with SB-334867 (two-way ANOVA interaction: F 1,26 =45.01test t, p<0,005), but this effect was not reversed by the pre-treatment with SB-334867 (test t, p>0,005). Conclusion: CR is able to promote antidepressant-like effect, possibly via OXA-OX1R signalling.
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Reversal of stress-induced anhedonia by the multimodel antidepressant, vortioxetine Abstract Vortioxetine, a newly approved antidepressant for the treatment of major depressive disorder has received special attention for its combination of antidepressant and pro-cognitive properties. Vortioxetine is a multimodal drug with a pharmacological profile distinct from conventional SSRIs as it works through two complementary mechanisms: 5-HT receptor activity modulation and SERT reuptake inhibition. Previous gene expression studies have suggested that vortioxetine has neuroplasticity
